COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa Psychedelics Investing
Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9 Pharmaceutical Investing
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib in Crohn's Disease Pharmaceutical Investing
The Gummy Project Secures First Repeat Order from Existing Customer Bard on the Beach Life Science Investing
Abbott Introduces Canada's First Remote Neuromodulation Patient-Care Technology, NeuroSphere Virtual Clinic, to Treat People with Chronic Pain and Movement Disorders* Pharmaceutical Investing
European Commission Approves RINVOQ® for the Treatment of Adults With Moderate to Severe Ulcerative Colitis Pharmaceutical Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
